Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
07 June 2023 | Story André Damons | Photo Supplied
Dr Michael Pienaar and Dr Edward C Netherlands
Dr Michael Pienaar, Senior Lecturer and specialist in the UFS Department of Paediatrics and Child Health, is a finalist in two categories of this year’s NSTF-South32 Awards. Dr Edward C Netherlands, Senior Lecturer in the UFS Department of Zoology and Entomology, is also in the running for his first NSTF-South32 Award.

Dr Michael Pienaar, Senior Lecturer and Specialist in the University of the Free State (UFS) Department of Paediatrics and Child Health, is a finalist in two categories of the 2023 NSTF-South32 Awards, popularly known as the ‘Science Oscars’ of South Africa.

Dr Pienaar, who has been working in paediatric critical care since 2019 and sees the care of critically ill children as his mission and calling in life, has been named a finalist in the TW Kambule-NSTF Award: Emerging Researcher and the NSTF-SAMRC Clinician-Scientist Award categories.

Another UFS staff member, Dr Edward C Netherlands, Senior Lecturer in the Department of Zoology and Entomology, is also a finalist in the TW Kambule-NSTF Award: Emerging Researcher category.

The NSTF-SAMRC Clinician-Scientist Award, sponsored by the South African Medical Research Council (SAMRC), is a new award for an outstanding contribution by a clinician-scientist, with a focus on work to enhance life and improve community health. This new category is modelled on the Emerging Researcher category.

‘Validating to have research recognised’

Dr Pienaar says it is humbling to be considered for these awards alongside formidable, accomplished, and innovative clinicians and scientists. “This is all somewhat surreal, as I was not anticipating being shortlisted as a finalist. It is validating to have had my research, which I am committed to, recognised on this platform. I am very grateful to the School of Clinical Medicine and the Faculty of Health Sciences and University of the Free State for nominating me for these awards.”

He was nominated by Dr Claire Armour Barrett, Clinical Research Director and Specialist Physician in the UFS School of Clinical Medicine.

Dr Pienaar says his current research focusses on applied machine learning in paediatric critical care. He has been working on the development of machine learning models that can be used in clinical practice to improve patient care.

“The work leading to these nominations focused on triage and identification of critically ill children in South Africa. Currently, I am working towards machine learning models implemented in point-of-care ultrasonography and mechanical ventilation.

“I am pleased just to be shortlisted for these awards. I think this provides important visibility for my work, which I feel has major long-term implications for clinical practice. I am also very happy to represent the research work being done in the Faculty of Health Sciences and the UFS on this platform.”

On what it will mean to win a ‘Science Oscar’, Dr Pienaar says, “While this would advance my career, I am very aware that all the candidates would be worthy winners. As it is, the opportunity to be a scholar is reward unto itself, and I am very privileged to be able to do the research I do. As ever, I am very grateful to the University and the Faculty of Health Sciences as well as the National Research Foundation for supporting my work.”

‘Honour and privilege’

Dr Netherlands, who was nominated by Prof Corli Witthuhn, former UFS Vice-Rector for Research and Internationalisation, says, “It is a great honour and privilege to represent the UFS.”

His work as a parasitologist and herpetologist involves specialised research in the study of blood parasites. His current research focuses on the diversity, evolution, and ecological implications of blood parasites in herpetofauna (reptiles and amphibians of a particular region).

“Being shortlisted as a finalist for this award will be a humbling achievement in my career, that may lead to new opportunities and new collaborations,” Dr Netherlands says. “Furthermore, being shortlisted provides a sense of validation and affirmation for the effort that has gone into conducting my research.”

The announcement of the winners will take place at the NSTF-South32 Awards Gala Event on 13 July 2023.

News Archive

#Women'sMonth: Save the children
2017-08-10

Description: Trudi O'Neill Tags: : rotaviruses, young children, Dr Trudi O’Neill, Department of Microbial, Biochemical and Food Biotechnology, vaccine 

Dr Trudi O’Neill, Senior lecturer in the Department of
Microbial, Biochemical and Food Biotechnology.
Photo: Anja Aucamp

Dr Trudi O’Neill, Senior lecturer in the Department of Microbial, Biochemical and Food Biotechnology, is conducting research on rotavirus vaccines.

Dr O’Neill was inspired to conduct research on this issue through her fascination with the virus. “The biology of rotaviruses, especially the genome structure and the virus’ interaction with the host, is fascinating.”

“In fact, it is estimated that, globally, ALL children will be infected with rotavirus before the age of five, irrespective of their socio-economic standing. However, infants and young children in poor countries are more vulnerable due to inadequate healthcare. The WHO estimates that approximately 215 000 deaths occur each year. This roughly equates to eight Airbus A380 planes, the largest commercial carrier with a capacity of approximately 500 seats, filled with only children under the age of five, crashing each week of every year.”

Alternative to expensive medicines 
“Currently, there are two vaccines that have been licensed for global use. However, these vaccines are expensive and poor countries, where the need is the greatest, are struggling to introduce them sustainably. It is therefore appealing to study rotaviruses, as it is scientifically challenging, but could at the same time have an impact on child health,” Dr O’Neill said.

The main focus of Dr O’Neill’s research is to develop a more affordable vaccine that can promote child vaccination in countries/areas that cannot afford the current vaccines.

All about a different approach 

When asked about the most profound finding of her research, Dr O’Neill responded: “It is not so much a finding, but rather the approach. My rotavirus research group is making use of yeast as vehicle to produce a sub-unit vaccine. These microbes are attractive, as they are relatively easy to manipulate and cheap to cultivate. Downstream production costs can therefore be reduced. The system we use was developed by my colleagues, Profs Koos Albertyn and Martie Smit, and allows for the potential use of any yeast. This enables us to screen a vast number of yeasts in order to identify the best yeast producer.”

Vaccination recently acquired a bad name in the media for its adverse side effects. As researcher, Dr O’Neill has this to say: “Vaccines save lives. By vaccinating your child, you don’t just protect your own child from a potentially deadly infection, but also other children in your community that might be too young to be vaccinated or have pre-existing health problems that prevents vaccination.” 

A future without rotavirus vaccination?

Dr O’Neill believes a future without rotavirus vaccination will be a major step backwards, as the impact of rotavirus vaccines has been profound. “Studies in Mexico and Malawi actually show a reduction in deaths. A colleague in Mozambique has commented on the empty hospital beds that amazed both clinicians and scientists only one year after the introduction of the vaccine in that country. Although many parents, mostly in developed countries, don’t have to fear dehydrating diarrhoea and potential hospitalisation of their babies due to rotavirus infection anymore, such an infection could still be a death sentence in countries that have not been able to introduce the vaccine in their national vaccination programmes,” she said. 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept